FDA accepts supplemental Biologics License Application for Roche's Polivy ... - GlobeNewswire

Retrieved on: 2022-08-16 17:03:03

Tags for this article:

RTT

Non-Hodgkin lymphoma

u.s. food and drug administration

Click the tags to see associated articles and topics

FDA accepts supplemental Biologics License Application for Roche's Polivy ... - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/08/16/2498709/0/en/FDA-accepts-supplemental-Biologics-License-Application-for-Roche-s-Polivy-combination-for-people-with-previously-untreated-diffuse-large-B-cell-lymphoma.html

Excerpt

Basel, 16 August 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the ...

Article found on: www.globenewswire.com

View Original Article